Cover Image
市場調查報告書

帶狀皰疹:開發中產品分析

Herpes Zoster (Shingles) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232833
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
帶狀皰疹:開發中產品分析 Herpes Zoster (Shingles) - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 75 Pages
簡介

帶狀皰疹,是伴隨強烈疼痛的水痘形成性的皮疹,由水痘、帶狀皰疹病毒引起。其症狀有發熱、發冷、頭痛、關節痛等。發病要素有年齡,免疫功能低等,治療利用抗組織胺藥物和止痛藥。

本報告提供帶狀皰疹治療藥的開發情形的相關調查,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等。

簡介

  • 調查範圍

帶狀皰疹概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

帶狀皰疹:企業開發中的治療藥

帶狀皰疹:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

帶狀皰疹:企業開發中的產品

帶狀皰疹的開發治療藥的企業

  • Astellas Pharma Inc.
  • Beijing Minhai Biotechnology Co., Ltd
  • ContraVir Pharmaceuticals, Inc.
  • Epiphany Biosciences, Inc.
  • Foamix Pharmaceuticals Ltd.
  • GeneOne Life Science, Inc.
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • NAL Pharmaceuticals Ltd.
  • ReceptoPharm, Inc.
  • TSRL, Inc.

帶狀皰疹:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • acyclovir
  • amenamevir
  • FV-100
  • GLS-5100
  • GSK-1437173A
  • herpes zoster vaccine
  • NAL-3221
  • NAL-3223
  • RPI-78M
  • TSR-087
  • V-212
  • valomaciclovir stearate

帶狀皰疹:最近的開發平台趨勢

帶狀皰疹:暫停中的計劃

帶狀皰疹:開發中止的產品

帶狀皰疹:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8493IDB

Summary

Global Markets Direct's, 'Herpes Zoster (Shingles) - Pipeline Review, H2 2016', provides an overview of the Herpes Zoster (Shingles) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles)
  • The report reviews pipeline therapeutics for Herpes Zoster (Shingles) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Herpes Zoster (Shingles) therapeutics and enlists all their major and minor projects
  • The report assesses Herpes Zoster (Shingles) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Herpes Zoster (Shingles) Overview
  • Therapeutics Development
    • Pipeline Products for Herpes Zoster (Shingles) - Overview
  • Herpes Zoster (Shingles) - Therapeutics under Development by Companies
  • Herpes Zoster (Shingles) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Herpes Zoster (Shingles) - Products under Development by Companies
  • Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc.
    • Beijing Minhai Biotechnology Co., Ltd
    • ContraVir Pharmaceuticals, Inc.
    • Epiphany Biosciences, Inc.
    • Foamix Pharmaceuticals Ltd.
    • GeneOne Life Science, Inc.
    • GlaxoSmithKline Plc
    • Merck & Co., Inc.
    • N & N Pharmaceuticals Inc.
    • NAL Pharmaceuticals Ltd.
    • NanoViricides, Inc.
    • ReceptoPharm, Inc.
    • TSRL, Inc.
    • XBiotech Inc
  • Herpes Zoster (Shingles) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acyclovir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amenamevir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FV-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GLS-5100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-1437173A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes zoster vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Shingles - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAL-3221 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAL-3223 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPI-78M - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Shingles - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TSR-087 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • V-212 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • valomaciclovir stearate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Herpes Zoster (Shingles) - Dormant Projects
  • Herpes Zoster (Shingles) - Discontinued Products
  • Herpes Zoster (Shingles) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
      • Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
      • Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug
      • Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
      • Oct 27, 2015: GSK's candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
      • Sep 08, 2015: Clinical trial for Cardiff's shingles treatment
      • Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain
      • Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
      • Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied
      • Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN
      • Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint
      • Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant
      • Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
      • Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles
      • Apr 09, 2013: Zoster Vaccine Effective Against Incident Herpes Zoster And Post-herpetic Neuralgia In Older US Population, Cohort Study Finds
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Herpes Zoster (Shingles), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc., H2 2016
  • Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
  • Herpes Zoster (Shingles) - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016
  • Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences, Inc., H2 2016
  • Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
  • Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science, Inc., H2 2016
  • Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Herpes Zoster (Shingles) - Pipeline by Merck & Co., Inc., H2 2016
  • Herpes Zoster (Shingles) - Pipeline by N & N Pharmaceuticals Inc., H2 2016
  • Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
  • Herpes Zoster (Shingles) - Pipeline by NanoViricides, Inc., H2 2016
  • Herpes Zoster (Shingles) - Pipeline by ReceptoPharm, Inc., H2 2016
  • Herpes Zoster (Shingles) - Pipeline by TSRL, Inc., H2 2016
  • Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Herpes Zoster (Shingles) - Dormant Projects, H2 2016
  • Herpes Zoster (Shingles) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Herpes Zoster (Shingles), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top